Obesity and prostate cancer incidence and mortality: A systematic review of prospective cohort studies

Urologia Internationalis

Volumn 92, Issue 1, 2014, Pages 7-14

  Golabek, Tomasz ^a   Bukowczan, Jakub ^c,d   Chłosta, Piotr ^b   Powroźnik, Jan ^a   Dobruch, Jakub ^a   Borówka, Andrzej ^a  

^a European Health Centre in Otwock   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Obesity; Prospective cohort studies; Prostate cancer

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WAIST HIP RATIO; CANCER RISK; REVIEW; WEIGHT GAIN;

HUMANS; INCIDENCE; MALE; OBESITY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84893315829     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000351325     Document Type: Article

References (61)

1. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, World Health Organization, 2009. http://www.who.int/healthinfo/global-burden- disease/GlobalHealthRisks-report- full. pdf (accessed on March 19, 2013
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-1727
3. Peytremann-Bridevaux I, Faeh D, Santos-Eggimann B: Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev Med 2007; 44: 442-446
4. Noria SF, Grantcharov T: Biological effects of bariatric surgery on obesity-related comorbidities. Can J Surg 2013; 56: 47-57
5. Adams KF, Leitzmann MF, Albanes D, et al: Body mass and colorectal cancer risk in the NIH-AARP cohort. Am J Epidemiol 2007; 166: 36-45
6. Olson SH, Trevisan M, Marshall JR, et al: Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 1995; 23: 141-149
7. Feigelson HS, Jonas CR, Teras LR, et al: Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004; 13: 220-224
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
9. Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, Esho JO: Effect of obesity on serum prostate-specific antigen in Nigerian men. Urol Int 2012; 89: 52-56
10. Castillejos-Molina R, Rodríguez-Covarrubias F, Sotomayor M, Gómez-Alvarado MO, Villalobos-Gollás M, Gabilondo F, Feria-Bernal G: Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int 2011; 87: 270-275
11. Mundhenk J, Hennenlotter J, Alloussi S, Selbherr D, Martzog JC, Todenhöfer T, Kruck S, Schwentner C, Stenzl A, Schilling D: Influence of body mass index, surgical approach and lymphadenectomy on the development of symptomatic lymphoceles after radical prostatectomy. Urol Int 2013; 90: 270-276
12. Buschemeyer WC 3rd, Freedland SJ: Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol 2007; 52: 331-343
13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. PLoS Med 2009; 6: E1000097
14. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA: Diet, anthropometric measures and prostate cancer risk: A review of prospective cohort and intervention studies. BJU Int 2004; 93: 1139-1150
15. Hayden JA, Côté P, Bombardier C: Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-437
16. Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, Manjer J, Engeland A, Nagel G, Almqvist M, Selmer R, Concin H, Tretli S, Jonsson H, Stattin P: Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012; 118: 6199-6206
17. Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, English DR, Giles GG: Weight change and prostate cancer incidence and mortality. Int J Cancer 2012; 131: 1711-1719
18. Dehal A, Garrett T, Tedders SH, Arroyo C, Afriyie-Gyawu E, Zhang J: Body mass index and death rate of colorectal cancer among a national cohort of U.S. adults. Nutr Cancer 2011; 63: 1218-1225
19. Chamberlain C, Romundstad P, Vatten L, Gunnell D, Martin RM: The association of weight gain during adulthood with prostate cancer incidence and survival: A populationbased cohort. Int J Cancer 2011; 129: 1199-1206
20. Burton A, Martin R, Galobardes B, Davey Smith G, Jeffreys M: Young adulthood body mass index and risk of cancer in later adulthood: Historical cohort study. Cancer Causes Control 2010; 21: 2069-2077
21. Stocks T, Hergens MP, Englund A, Ye W, Stattin P: Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer 2010; 127: 1660-1668
22. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E: A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden). Cancer Causes Control 2007; 18: 1107-1121
23. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjønneland A, Severinsen MT, Overvad K, Rohrmann S, Kaaks R, Trichopoulou A, Zoi G, Trichopoulos D, Pala V, Palli D, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, May A, Manjer J, Wallström P, Stattin P, Hallmans G, Buckland G, Larraña-ga N, Chirlaque MD, Martínez C, Redondo Cornejo ML, Ardanaz E, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E: Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 3252-3261
24. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007; 121: 1571-1578
25. Littman AJ, White E, Kristal AR: Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165: 1271-1279
26. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF: Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684
27. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA: Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004; 63: 253-258
28. Engeland A, Tretli S, Bjørge T: Height, body mass index, and prostate cancer: A follow-up of 950000 Norwegian men. Br J Cancer 2003; 89: 1237-1242
29. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ: Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345-353
30. Lee IM, Sesso HD, Paffenbarger RS Jr: A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control 2001; 12: 187-193
31. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA: Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 2000; 151: 541-549
32. Andersson SO, Wolk A, Bergström R, Adami HO, Engholm G, Englund A, Nyrén O: Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389
33. Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB, Lubaroff DM, Wallace RB: Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997; 8: 229-238
34. Chyou PH, Nomura AM, Stemmermann GN: A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. Int J Cancer 1994; 57: 313-317
35. Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T: Animal fat consumption and prostate cancer: A prospective study in Hawaii. Epidemiology 1994; 5: 276-282
36. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL: Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989; 129: 511-517
37. Mills PK, Beeson WL, Phillips RL, Fraser GE: Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64: 598-604
38. Snowdon DA, Phillips RL, Choi W: Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244-250
39. Kaaks R, Lukanova A, Rinaldi S, et al: Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12: 309-315
40. Pasquali R, Casimirri F, Cantobelli S, et al: Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991; 40: 101-104
41. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E: Serum adipocytokine levels in prostate cancer patients. Urol Int 2009; 82: 203-208
42. Ribeiro R, Lopes C, Medeiros R: The link between obesity and prostate cancer: The leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 2006; 9: 19-24
43. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591
44. Severi G, Morris HA, MacInnis RJ, et al: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 86-91
45. Chen C, Weiss NS, Stanczyk FZ, et al: Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12: 1410-1416
46. Platz EA, Leitzmann MF, Rifai N, et al: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262-1269
47. Cunha GR, Hayward SW, Wang YZ, et al: Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003; 107: 1-10
48. Hsing AW, Reichardt JK, Stanczyk FZ: Hormones and prostate cancer: Current perspectives and future directions. Prostate 2002; 52: 213-235
49. Massengill JC, Sun L, Moul JW, et al: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-1675
50. Giovannucci E, Rimm EB, Stampfer MJ, et al: Diabetes mellitus and risk of prostate cancer. Cancer Causes Control 1998; 9: 3-9
51. Will JC, Vinicor F, Calle EE: Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999; 10: 313-318
52. Hsing AW, Gao YT, Chua S, et al: Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 67-71
53. Yu H, Rohan T: Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489
54. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS: Hormonal predictors of prostate cancer: A meta-Analysis. J Clin Oncol 2000; 18: 847-853
55. Shuldiner AR, Yang R, Gong DW: Resistin, obesity and insulin resistance-The emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345: 1345-1346
56. Stattin P, Soderberg S, Hallmans G, et al: Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345
57. Somasundar P, Frankenberry KA, Skinner H, et al: Prostate cancer cell proliferation is influenced by leptin. J Surg Res 2004; 118: 71-82
58. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC: Leptin induces cell migration and expression of growth factors in human prostate cancer cells. Am J Surg 2004; 188: 560-565
59. Saglam K, Aydur E, Yilmaz M, Goktas S: Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169: 1308-1311
60. Statin P, Kaaks R, Johansson R, et al: Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 474-475
61. Chang S, Hursting SD, Contois JH, et al: Leptin and prostate cancer. Prostate 2001; 46: 62-67